

02-15-02

PATENT



UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231
Sir:

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: USAV2001/0002 US NP

INVENTORS: C. Smith et al

TITLE: **METHOD OF TREATING OF
DEMYELINATING DISEASES OR CONDITIONS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

2-14-2002

Date of Deposit.

Genelia Leakey

Signature

EK897872138 US

Express Mail No.

APPLICATION ELEMENTS

1. <input type="checkbox"/>	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	Total Pages	48
2. <input checked="" type="checkbox"/>	Specification (preferred arrangement set forth below)	Total Pages	48
	- Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure		
3. <input checked="" type="checkbox"/>	Drawing(s) (35 U.S.C. 113) (Informal)	Total Sheets	11
4. Oath or Declaration		Total Pages	2
a. <input checked="" type="checkbox"/>	Newly <u>Unexecuted</u>		
b. <input type="checkbox"/>	Copy from a prior application (37 CFR § 1.63(d)) (for continuation/divisional with Box 16 completed)		
i. <input type="checkbox"/>	<u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).		
5. <input type="checkbox"/>	Microfiche Computer Program (Appendix)		
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)			
a. <input type="checkbox"/>	Computer Readable Copy		
b. <input type="checkbox"/>	Paper Copy (identical to computer copy)		
c. <input type="checkbox"/>	Statement verifying identity of above copies		

If a **CONTINUING** Application, check appropriate box, and supply the requisite information:
 Continuation Divisional Continuation-in-part
of prior application no: _____, filed _____
Examiner _____, Group/Art Unit _____.
(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of U.S. Provisional Application No. 60/268,846, filed February 15, 2001 and GB 0119435.6, Filed August 9, 2001. (The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (*cover sheet & document(s)*)
8. 37 CFR §3.73(b) Statement Power of Attorney
(*when there is an assignee*)
9. English Translation Document (*if applicable*)
10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
11. Preliminary Amendment
12. Return Receipt Postcard (MPEP 503)
(*Should be specifically itemized*)
13. *Small Entity Statement(s) Statement filed in prior application, Status still proper and desired
(PTO/SB/09-12)
14. Certified Copy of Priority Document(s)
(*if foreign priority is claimed*)
15. Other: EFS

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487
(Insert Customer No. or Attach bar code label here)


Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Mail Code: EMC-G1
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. AVUS01/0002 US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Complete if Known

Application Number	NOT YET ASSIGNED
Filing Date	FILED HEREWITH
First Named Inventor	Craig P. Smith et al
Examiner Name	
Group / Art Unit	NOT YET ASSIGNED
Attorney Docket No.	USA2001/0002 US NP

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 974.00)

METHOD OF PAYMENT (check all that apply)					FEE CALCULATION (continued)				
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None <input checked="" type="checkbox"/> Deposit Account					3. ADDITIONAL FEES				
					Large Entity		Small Entity		
					Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
					105	130	205	65	Surcharge - late filing fee or oath
					127	50	227	25	Surcharge - late provisional filing fee or cover sheet
					139	130	139	130	Non-English Specification
					147	2,520	147	2,520	For filing a request for reexamination
					112	920*	112	920*	Requesting publication of SIR prior to Examiner action
					113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action
					115	110	215	55	Extension for reply within first month
					116	400	216	200	Extension for reply within second month
					117	920	217	460	Extension for reply within third month
					118	1,440	218	720	Extension for reply within fourth month
					128	1,960	228	980	Extension for reply within fifth month
					119	320	219	160	Notice of Appeal
					120	320	220	160	Filing a brief in support of an appeal
					121	280	221	140	Request for oral hearing
					138	1,510	138	1,510	Petition to institute a public use proceeding
					140	110	240	55	Petition to revive - unavoidable
					141	1,280	241	640	Petition to revive - unintentional
					142	1,280	242	640	Utility issue fee (or reissue)
					143	460	243	230	Design issue fee
					144	620	244	310	Plant issue fee
					122	130	122	130	Petitions to the Commissioner
					123	50	123	50	Petitions related to provisional applications
					126	180	126	180	Submission of Information Disclosure Stmt
					581	40	581	40	Recording each patent assignment per property (times number of properties)
					146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))
					149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))
					179	740	279	370	Request for Continued Examination (RCE)
					169	900	169	900	Request for expedited examination of a design application
					Other fee (specify)				
					*Reduced by Basic Filing Fee Paid				SUBTOTAL (3) (\$)


**or number previously paid, if greater; For Reissues, see above

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Complete (If applicable)

Name (Print/Type)	Barbara E. Kurys	Registration No. (Attorney/Agent)	34,650	Telephone	(908) 231-2965
Signature				Date	2-14-2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. Aventis Pharmaceuticals Inc. template